D-0485-2023 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0485-2023 was initiated by Direct Rx on Mar 13, 2023 and is designated Class II. Reason for recall: cGMP deviations The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 30 count: 5 bottles; 90 count: 53 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 5, 2023
Initiation Date
Mar 13, 2023
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
30 count: 5 bottles; 90 count: 53 bottles

Product description

Simvastatin, USP, 20 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0446-30 b) 90-count bottle, NDC 61919-0446-90, Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534

Reason for recall

cGMP deviations

Distribution pattern

Nationwide in the USA

Code information

a) [30-count bottles] Lot, expiry: 09JA2312 , exp 2/28/2025; b) [90-count bottles] Lot, expiry: 22OC2111, exp 1/31/2023; 13OC2120, exp 3/31/2023; 16JY2104, exp 12/31/2023; 09AU2125 , exp 1/31/2024 ; 28JY2125 , exp 1/31/2024 ; 23SE2115 , exp 3/31/2024 ; 23SE2115 , exp 3/31/2024 ; 07JA2211 , exp 5/31/2024 ; 27JA2214 , exp 5/31/2024 ; 15AP2224 , exp 6/30/2024 ; 24MA2221 , exp 6/30/2024 ; 16AU2214 , exp 6/30/2024 .

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0485-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0485-2023. Report a data issue: hello@regdatalab.com.